Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Target Price from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued a report on the stock in the last year is $6.38.

Several brokerages have commented on TSHA. Canaccord Genuity Group dropped their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. BMO Capital Markets assumed coverage on Taysha Gene Therapies in a research report on Thursday, June 27th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, Piper Sandler dropped their target price on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a research report on Monday, July 1st.

Taysha Gene Therapies Stock Down 5.6 %

Taysha Gene Therapies stock opened at $2.03 on Tuesday. Taysha Gene Therapies has a fifty-two week low of $1.27 and a fifty-two week high of $4.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The firm has a market capitalization of $379.65 million, a price-to-earnings ratio of -4.14 and a beta of 0.41. The company’s 50 day simple moving average is $2.20 and its 200 day simple moving average is $2.59.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. During the same quarter last year, the business posted ($0.38) EPS. As a group, sell-side analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of the stock in a transaction on Thursday, June 27th. The shares were purchased at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the transaction, the insider now directly owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC grew its position in shares of Taysha Gene Therapies by 328.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares during the period. Artal Group S.A. lifted its stake in Taysha Gene Therapies by 0.7% in the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after purchasing an additional 24,444 shares during the last quarter. StemPoint Capital LP bought a new position in Taysha Gene Therapies during the first quarter worth about $3,122,000. Quantum Private Wealth LLC increased its position in Taysha Gene Therapies by 4.6% during the second quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock worth $1,636,000 after buying an additional 32,000 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Taysha Gene Therapies in the second quarter valued at approximately $1,018,000. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.